Members of the U.S. delegation pose for a group photo at Edan Instruments Inc. in Pingshan District. Photos from Investment Promotion and Service Bureau of Pingshan District 

Representatives from Global Biopharma Partnerships, B+labs, Robin Hood Ventures, Lachman Consultants and other U.S. organizations visited Pingshan District on Sept. 8 to explore biopharmaceutical R&D, incubation, and opportunities for international cooperation. 

The group toured Edan Instruments Inc., ScienCare Pharmaceutical Co., Ltd., and the Biomedical Enterprise Accelerator Phase 2, and expressed strong appreciation for Pingshan’s biopharmaceutical ecosystem.

Edan Instruments is a leading Chinese high-tech medical device R&D and manufacturing company. Leveraging technologies such as microfluidics and biosensors, it was the first in the industry to launch a dry blood gas analyzer and now exports multiple products to European and U.S. markets. ScienCare Pharmaceutical focuses on the R&D, production, and sales of addiction‑treatment drugs, including medications for alcohol use disorder. The Biomedical Enterprise Accelerator Phase 2 provides high-quality office and R&D space for biopharmaceutical companies.

Members of the U.S. delegation visit a company in Pingshan District.

Holly Meng, founder and CEO of Global Biopharma Partnerships, said she was impressed by Pingshan’s full-fledged industrial chain and supportive policies, and sees broad prospects for international cooperation in strategic consulting, incubation, and global market expansion between Shenzhen and the U.S.

An official from the Shenzhen Municipal Investment Promotion Bureau added that the city will build more platforms to foster exchanges and collaboration with U.S. partners in the biopharmaceutical sector.